RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Cytokine Storm, SARS-CoV-2

In brief

The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively. The investigators hypothesize that Doxycycline will will improve survival and reduce morbidity in SARS-CoV-2 infected patients. A secondary aim is to identify genetic variants that predict either an unusually mild disease or an unusually severe disease - knowledge that can be used to design new and precise medications and to be able to predict patients who might get into early trouble and to therefore hospitalize them.

Key facts

Study ID
NCT04433078
Run by
Temple University
People needed
0
Starts
2020-06-22
Expected to finish
2021-04-13
Last updated by the study team
2021-04-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.